BioCryst Pharmaceuticals Grants Inducement Stock Options
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) has recently enriched its team by granting stock options as part of its strategic growth. The compensation committee of BioCryst’s board announced the granting of stock options to four newly hired individuals, amounting to a total of 57,100 shares. Additionally, restricted stock units (RSUs) covering 46,400 shares were also issued. These benefits were formally introduced on December 1, to incentivize the new employees as they embarked on their journey with BioCryst.
Details of the Stock Options and RSUs
The options come with an exercise price set at $7.13 per share, which aligns with the closing stock price of BioCryst on the day of the grant. Both the options and RSUs are structured to vest in four equal installments over four years, starting from the first anniversary of the grant date. This structure is a commitment to ensure the continuity of employment for the new hires, fostering their long-term engagement with BioCryst. Furthermore, each option will retain a lifespan of ten years, giving employees ample time to exercise their options before expiration.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals stands out as a pioneering global biotechnology firm dedicated to the advancement and commercialization of innovative treatments for hereditary angioedema (HAE) and other rare diseases. The company has made significant strides in providing effective solutions, including the pioneering oral treatment, ORLADEYO (berotralstat), which serves as the first oral plasma kallikrein inhibitor prescribed once a day. BioCryst's commitment to R&D drives its diverse pipeline, which is comprised of potential first-in-class and best-in-class treatments for various rare conditions.
BioCryst's Commitment to Rare Diseases
With its focus on rare diseases, BioCryst is motivated to improve the quality of life for those affected by these conditions. The company’s extensive pipeline includes both small-molecule oral therapies and injectable protein therapeutics aimed at treating a broad spectrum of rare diseases. This dedicated pursuit reflects BioCryst's ethos of putting patients first and the urgent need for novel therapies.
Company Contact Information
For those interested in further information regarding BioCryst's initiatives or investor relations, the company can be reached through the following contacts:
Investor Relations
Users can get in touch at investorrelations@biocryst.com for inquiries related to investments and financial data.
Media Inquiries
For media-related questions, reach out via media@biocryst.com. BioCryst is enthusiastic about engaging with the public and sharing its advancements in biotechnology.
Frequently Asked Questions
What are the stock options granted by BioCryst Pharmaceuticals?
BioCryst granted stock options to newly hired employees, including 57,100 share options and 46,400 RSUs, aimed at motivating new talent.
What is ORLADEYO?
ORLADEYO (berotralstat) is BioCryst's first oral treatment for hereditary angioedema, marking a significant innovation in rare disease therapies.
How do the stock options vest?
The options vest over four years in equal installments, starting after the first anniversary of the grant date, ensuring employees' long-term commitment.
How can I contact BioCryst Pharmaceuticals?
For investor inquiries, email investorrelations@biocryst.com. For media, use media@biocryst.com.
What is BioCryst's focus area?
BioCryst concentrates on developing medicines for rare diseases, especially hereditary angioedema, to enhance patient quality of life.
